Miguel Diaz, MD
Interventional Cardiology · Hialeah, FLNPI 1013118322
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $328,166 of the $383,435 with a category attached, or 85.6%. 58 manufacturers reported payments, led by Amgen at 29.1% of the total. Reporting peaked in 2019 at $89,472 and has fallen 81.3% since, to $16,747 in 2025. Among interventional cardiology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 883 payments — averaging $434.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$112K
- AstraZeneca$77K
- Chiesi USA, Inc.$66K
- Abbott$53K
- Shockwave Medical, Inc$34K
- Boston Scientific$12K
- plus $30K from 52 others
Across 25 payments — averaging $4556.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Chiesi USA, Inc.$112K
- AstraZeneca$2K
What the payments were for
- Consulting fees$9,6903%
- Speaking & faculty fees$328,16686%
- Travel & lodging$10,4043%
- Food & beverage$35,0019%
- Education$1740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$110,909
- KENGREAL$64,532
- BRILINTA$58,238
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$34,221
- FARXIGA$18,414
- MitraClip System$14,897
- MitraClip$13,091
- Mitra Clip system$12,206
- DyeVert$5,455
- Supera peripheral stent system$4,399
- Impella$4,129
- Edwards SAPIEN 3 Transcatheter Heart Valve$3,251
- Diamondback Coronary$2,480
- AMPLATZER TALISMAN$2,164
- AMPLATZER Occluders$2,130
- BioMonitor$1,341
- WATCHMAN FLX$898
- AVEIR$834
- Acticor 7 VR-T DX$795
- Edora$672
How this compares
$383,435 in reported general payments places this provider in the 95th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 118 | $137,867 |
| EntrestoSacubitril/Valsartan | 119 | $128,002 |
| Repatha SureclickEvolocumab | 163 | $121,138 |
| FarxigaDapagliflozin Propanediol | 70 | $67,812 |
| BrilintaTicagrelor | 91 | $62,236 |
| XareltoRivaroxaban | 56 | $54,378 |
| MultaqDronedarone Hcl | 11 | $23,000 |
| VascepaIcosapent Ethyl | 18 | $11,380 |
| Praluent PenAlirocumab | 16 | $8,064 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 17 | $5,566 |
| Amiodarone Hcl | 41 | $2,999 |
| Metoprolol Succinate | 197 | $1,363 |
| Ranolazine ErRanolazine | 18 | $1,239 |
| Atorvastatin Calcium | 183 | $990 |
| Rosuvastatin Calcium | 83 | $930 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $596 | $137,867118 claims |
| AstraZenecaFarxiga, Brilinta | $77,001 | $130,048161 claims |
| NovartisEntresto | $845 | $128,002119 claims |
| Johnson & JohnsonXarelto | $116 | $54,37856 claims |
| Sanofi-aventis U.S. LLCMultaq | $145 | $23,00011 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $19 | $5,56617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Hialeah
- Francisco DieguezHialeah$60K
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Douglas EbersoleLakeland$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.